Orna Therapeutics Establishes Strategic Collaboration with Vertex ...
Additionally, Orna is further eligible to receive up to $365 million in additional option fees and milestones per product for up to ten additional products if Vertex options rights in additional indications. Orna will be eligible to receive tiered royalties on future net sales of any products that may result from this collaboration.
Vertex and Orna sign partnership to improve efficiencies of gene ...
1 day ago · Vertex will pay Orna $65m upfront, partly through a convertible note, and Orna is eligible for up to $635m in milestone payments for SCD and TDT products. Additionally, Orna could receive up to $365m per product for up to ten additional indications, alongside royalties on future sales. ... Tick here to opt out of curated industry news, reports ...
Vertex, startup Orna to partner on gene editing research
3 days ago · Vertex Pharmaceuticals will work together with Orna Therapeutics over the next three years to develop technology that would help enable “in vivo” gene therapies for sickle cell disease and beta thalassemia. Under the deal announced Tuesday, Vertex will pay Orna $65 million upfront, a sum that includes an investment via a convertible note.
Orna Therapeutics Establishes Strategic Collaboration with Vertex ...
2 days ago · Additionally, Orna is further eligible to receive up to $365 million in additional option fees and milestones per product for up to ten additional products if Vertex options rights in additional ...
Orna Therapeutics, Vertex Pharma Enter Three-year Research ...
2 days ago · Also, Orna is eligible to receive up to $365 million in additional option fees and milestones per product for up to ten additional products if Vertex options rights in additional indications.
Vertex and Orna team up to develop new blood disorder …
2 days ago · Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ReNAgade in May 2024 for an undisclosed amount—could also make up ...
Orna Therapeutics, Vertex Pharma Enter Three-year Research ...
2 days ago · Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to utilize Orna's proprietary LNP delivery solutions to enhance Vertex's efforts in developing next generation gene editing therapies for patients with Sickle Cell Disease and …
Vertex Pharmaceuticals, Orna Therapeutics announce research ...
3 days ago · Additionally, Orna is further eligible to receive up to $365M in additional option fees and milestones per product for up to ten additional products if Vertex options rights in additional indications.
Orna Therapeutics collaborates with Vertex to develop …
2 days ago · Additionally, Orna is further eligible to receive up to $365 million in additional option fees and milestones per product for up to ten additional products if Vertex options rights in additional ...
Vertex thinks beyond Casgevy with Orna gene-editing pact
2 days ago · Plus, Orna could get up to $365 million in additional option fees and milestones per product if Vertex options rights in additional conditions. Vertex is funding the three-year research ...
- Some results have been removed